# Sydnexis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sydnexis

- Industry: Biotechnology
- Headquarters: Del Mar, US
- Website: www.sydnexis.com
- Total disclosed funding: $45M
- Latest round: Series B (Jul 10, 2021)
- Investors on record: 6

## About

Based in California, US, and founded in 2014, Sydnexis, Inc. operates as a clinical-stage biopharmaceutical company. In April 2024, Sydnexis, Inc. raised USD 999,807 million in Series B funding from unspecified investors. The Series B funding values Sydnexis, Inc. at USD 82.1 million post-money. As of 2024, the company is led by its president, Patrick Johnson, and CEO, Perry J. Sternberg.

Sydnexis develops treatments for childhood myopia, also known as nearsightedness. The firm’s pipeline product includes SYD-101, which is an investigational low-dose atropine sulfate ophthalmic solution to slow down the progression of myopia in children.

## Funding rounds

- Series B, Jul 10, 2021, $45M — Bluestem Capital Company, Longitude Capital, RA Capital Management, Medicxi, Visionary Venture Fund, SC Master Fund

## Investors

- Bluestem Capital Company (https://capitalatlas.ai/funds/bluestem-capital-company) — Series B
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series B
- Visionary Venture Fund (https://capitalatlas.ai/funds/visionary-venture-fund) — Series B
- SC Master Fund (https://capitalatlas.ai/funds/sc-master-fund) — Series B